Physician profile
Michael D White
NPI 1871848853
$1,878.99
in general payments reported to CMS, 2019-2025
9 companies · $136 in 2025
The $136 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $56.25 · 2024: $1,687 · 2025: $136.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,258 · Travel and Lodging: $621.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,258.11 |
| Travel and Lodging | $620.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,169.34 | 2024-2025 | Vercise, General - Dbs |
| Lilly USA, LLC | $285.49 | 2024-2025 | Kisunla, Emgality, Reyvow |
| Pfizer INC. | $256.07 | 2023-2025 | |
| Springworks Therapeutics, INC. | $42.81 | 2025 | Gomekli |
| Teva Pharmaceuticals USA, INC. | $36.90 | 2024-2025 | Austedo Xr, Austedo Xr |
| Acadia Pharmaceuticals INC | $24.06 | 2024 | Daybue |
| Novo Nordisk INC | $23.47 | 2024 | Wegovy |
| Amylyx Pharmaceuticals, INC. | $23.11 | 2023 | Relyvrio |
| Bayer Healthcare Pharmaceuticals INC. | $17.74 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.